Cancer Pharmacogenomics and Targeted Therapies

We are pleased to announce the inaugural Wellcome Trust Scientific Conference on Cancer Pharmacogenomics and Targeted Therapies.
The development of new cancer therapies is increasingly guided by our understanding of the molecular basis of cancer. As worldwide efforts are beginning to provide a comprehensive description of the genomic, transcriptomic and epigenomic changes that occur in cancer, the field of cancer pharmacogenomics will be at the forefront of a new generation of rationally designed cancer therapies incorporating molecular biomarkers. These hold the promise of improved clinical responses by enabling the stratification of patients most likely to benefit from a specific treatment.
This conference is aimed at scientists and clinician-scientists in academia or industry and will seek to address many of the key challenges in the design, development and clinical implementation of targeted cancer therapies.

Scientific topics will include:
• Cancer Genomics
• Drugging the Cancer Genome
• Experimental and pre-clinical therapeutic models
• Combating drug resistance
• Molecular biomarkers in the clinic
+ show speakers and program
Confirmed speakers include:
Bissan Al-Lazikani The Institute of Cancer Research, London, UK
Alberto Bardelli Institute for Cancer Research and Treatment at Candiolo, Italy
Rene Bernards The Netherlands Cancer Institute
Lynda Chin MD Anderson Cancer Centre, USA
Johann de Bono The Institute of Cancer Research, London, UK
Julian Downward CRUK London Research Institute, UK
Mikala Egeblad Cold Spring Harbor Laboratory, USA
Jeff Engelman Massachusetts General Hospital Cancer Center, USA
Manel Esteller Bellvitge Biomedical Research Institute, Spain
Keith Flaherty Massachusetts General Hospital, USA
Levi Garraway Dana Faber Cancer Institute, USA
Ultan McDermott Wellcome Trust Sanger Institute, UK
Stefan Pfister German Cancer Research Center
David Rees Astex Pharmaceuticals, USA
Tomi Sawyer AILERON Therapeutics, USA
David B. Solit Memorial Sloan-Kettering Cancer Center, USA
Mike Stratton Wellcome Trust Sanger Institute, UK
Dave Tuveson Cold Spring Harbor Laboratory, USA
Robert Vries Hubrecht Institute, The Netherlands
Lodewyk Wessels The Netherlands Cancer Institute
Paul Workman Institute of Cancer Research, London, UK

15 Sep - 17 Sep 2013
United Kingdom
meeting website